Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diclofenac for Prevention of Post-ERCP Pancreatitis
NCT03595150Phase 3Not yet recruiting
- Sponsor
- Karolinska Institutet
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of diclofenac in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by Karolinska Institutet. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
diclofenac
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT03595150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595150.